Early results demonstrate the potential of personalized 3D-printed shields for protecting healthy GI tissue in patients undergoing radiotherapy for prostate cancer.
The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era.
This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.
Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence following nephrectomy.
